Small Cell Lung CancerPhase 1ICARNCT03467360
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
A Phase 1 study testing acetazolamide in combination with platinum and etoposide-based radiochemotherapy and acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC in people with Small Cell Lung Cancer, run by Centre Antoine Lacassagne at 2 sites in 2 countries.
Trial summary
The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Small Cell Lung Cancer
- What is being tested?
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy and acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 2 Aug 2019to 27 Apr 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > or = 18 years,
- Performance Status 0 to 2,
- Patient with an histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer,
- Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group) or Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group) Note: The decision of the Multidisciplinary Consultation Team must be notified in the patient's medical file,
- Evaluation lesion according to the criteria RECIST 1.1 and / or according to the criteria PERCIST 1.0,
- Women of childbearing potential must have a negative serum pregnancy test within 72 hours of the first administration of the study treatment,
Show all 10Show fewer
- If the patient is a woman of childbearing potential, she must be surgically sterile or agree to use two adequate methods of contraception throughout the duration of the study until 1 month after the last administration of the study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,
- If the male patient has one or more female partners of childbearing age, he / she must agree to use an adequate method of contraception, starting at the first administration of the study treatment up to 1 month after the last administration of the treatment. of the study, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,
- Patient willing and able to provide written informed consent/assent for the trial,
- Patient affiliated with a health insurance system.
Who cannot join
- Patient with metastatic disease,
- History of thoracic irradiation or near / in the thoracic irradiation field,
- Patient who refuses to participate in the study or unable to agree,
- Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure:
- COPD grade IV according to the GOLD classification,
- Some GOLD III COPD and any patient with a respiratory defect defined as: oxygen dependence and / or FEV1 <40% normal and / or, DLCO <40% predictive value and / or vital capacity <40% predictive value,
Show all 10Show fewer
- Contraindication to acetazolamide: hypersensitivity to acetazolamide, severe hepatic, renal or adrenal insufficiency, sulfonamide intolerance, history of renal colic, allergy to wheat other than celiac disease,
- Patient currently receiving one or more treatments described in section 6.9 of the protocol,
- History of cancer, with the exception of cancers in complete remission for more than 5 years, completely resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer,
- People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
France1 site, 1 recruiting
- Recruiting
Centre Antoine Lacassagne
Nice, 06189
Jérôme Doyen, MD, +33492031270, jerome.doyen@nice.unicancer.fr
About this study
The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to:
- The over-expression of carbonic anhydrases in this type of cancer,
- The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines,
- The observed synergy between irradiation and inhibition of carbonic anhydrases,
- Potential anti-tumor immune effect caused by decreased extracellular acidity.
Read the detailed description
Compared with healthy cells, glucose metabolism is greatly modified in cancer cells because of their highly proliferative character. This differential tumor / healthy tissue property is an opportunity to be able to propose a treatment whose therapeutic gain can be major (targeted treatment). Preclinical studies are multiple and showed that the targeting of overexpressed proteins (carbonic anhydrases) and involved in glycolytic metabolism can lead to a significant anti-tumor effect. This has never been tested in humans.
Acetazolamide is a molecule commonly used for non carcinologic purposes but has demonstrated anti-tumor activity in preclinical studies; there is also synergy radiotherapy / targeting of carbonic anhydrases. Therefore, the investigators propose to study the combination of acetazolamide / radiotherapy / chemotherapy with platinum and etoposide in localized Small Cell Lung cancer, or associated with radioimmunotherapy (extensive SCLC).
This would be the first study:
- targeting glucose metabolism,
- testing the effectiveness of acetazolamide in oncology,
- testing the synergy radiotherapy / targeting glycolytic metabolism,
- trying to manipulate the anti-tumor immune system indirectly, by decreasing extracellular acidosis.
- Conditions
- Small Cell Lung Cancer
- Being tested
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy, acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
- Keywords
- acetazolamide
- Medical subject headings
- Small Cell Lung Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
acetazolamide in combination with platinum and etoposide-based radiochemotherapyDrug
Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
acetazolamide in combination with radioimmunotherapy in patients with extensive SCLCDrug
acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
| Study group | Role | What they receive |
|---|---|---|
| Localized SCLC | Experimental | non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer Receives: Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapy |
| Extensive SCLC | Other | non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with radioimmunotherapy in patients with extensive small cell lung cancer Receives: Drug: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC |
What is being measured
The primary outcome is the main question the study is designed to answer.
To identify the Tolerated Maximum Dose (DMT) and Recommended Dose (DR) of acetazolamide in combination with radiotherapy combined with platinum and etoposide chemotherapy (localized SCLC) or with radioimmunotherapy (extensive SCLC)
The frequency of limiting dose toxicities determined by the number of Adverse Events as Assessed by CTCAE v4.03 :
- during the 6 weeks of treatment with acetazolamide / chemoradiation based on platinum and etoposide and in the first 6 months of follow-up after the last administration of the treatment
- during the 10 days of treatment with acetazolamide / radioimmunotherapy and in the first 6 months after the last administration of the treatment with radioimmunotherapy, for the "extensive SCLC" subgroup
Measured: 8 months
Secondary outcomes (9)
To determine the overall tolerance of the association acetazolamide and radiochemotherapy (localized SCLC) or of the association acetazolamide and radioimmunotherapy (extensive)SCLC)
The overall tolerability of the treatments will be measured by clinical (performance status), laboratory (blood sample), and paraclinical evaluations (ETT, EFR) and defined on the NCI CTCAE V4.03 scale
Measured: 27 months
To evaluate the effectiveness of the treatment
The tumor response (complete or partial, stabilization, progression) will be performed by Morphological evaluations using a scanner according to RECIST 1.1 criteria
Measured: 24 months
To evaluate the effectiveness of the treatment
The tumor response (complete or partial, stabilization, progression) will be performed by Metabolic evaluations using a PET-CT scan according to the criteria PERCIST 1.0
Measured: 24 months
To identify predictive factors for response to acetazolamide
The evaluation of predictive factors of acetazolamide response will be determined by serum CAIX and CAXII levels (in the 7 days before the start of acetazolamide and the end-of-treatment visit)
Measured: 3 months
To identify predictive factors for response to acetazolamide
The evaluation of predictive factors of acetazolamide response will be determined by:
- The initial 18-FDG PET-CT scan (SUVmax, SULpeak) fixation intensity and 3 months after treatment,
Measured: 30 months
To evaluate progression-free survival at 24 months
To determine the delay between the date of inclusion and the date of progression or death
Measured: 24 months
To evaluate overall survival at 24 months
To determine the delay between the date of inclusion and the date of death
Measured: 24 months
To determine the compliance of acetazolamide
Compliance assessment will be done using Girerd's questionnaire
Measured: 27 months
To evaluate the quality of life
Quality of life will be determined using EORTC QLQC30 questionnaire
Measured: 27 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2018
- Study start2 Aug 2019
- Primary completion27 Oct 2026 (estimated)
- Study completion27 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Phase I study with a prospective, multicenter, non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized Small cell lung cancer or in combinaison with radioimmunotherapy in patients with extensive Small cell lung cancer
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Antoine Lacassagne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vanessa VIDAL, Study director, Centre Antoine Lacassagne
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03467360
- Sponsor's protocol ID
- 2017/14
- Other IDs
- 2022-503093-36-00, 2017-002160-40, 2017
- Acronym
- ICAR
- Status last verified
- Jan 2026
- First submitted
- 18 Jan 2018
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
- ClinicalTrials.gov ID
- NCT03467360
- Acronym / sponsor ID
- ICAR / 2017/14
- Conditions
- Small Cell Lung Cancer
- Keywords
- acetazolamide
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Centre Antoine LacassagneUniversity, hospital or other
- Study start
- 2 Aug 2019 (actual)
- Primary completion
- 27 Oct 2026 (estimated)
- Study completion
- 27 Apr 2027 (estimated)
- First posted
- 16 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to:
- The over-expression of carbonic anhydrases in this type of cancer,
- The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines,
- The observed synergy between irradiation and inhibition of carbonic anhydrases,
- Potential anti-tumor immune effect caused by decreased extracellular acidity.
Detailed description
Compared with healthy cells, glucose metabolism is greatly modified in cancer cells because of their highly proliferative character. This differential tumor / healthy tissue property is an opportunity to be able to propose a treatment whose therapeutic gain can be major (targeted treatment). Preclinical studies are multiple and showed that the targeting of overexpressed proteins (carbonic anhydrases) and involved in glycolytic metabolism can lead to a significant anti-tumor effect. This has never been tested in humans.
Acetazolamide is a molecule commonly used for non carcinologic purposes but has demonstrated anti-tumor activity in preclinical studies; there is also synergy radiotherapy / targeting of carbonic anhydrases. Therefore, the investigators propose to study the combination of acetazolamide / radiotherapy / chemotherapy with platinum and etoposide in localized Small Cell Lung cancer, or associated with radioimmunotherapy (extensive SCLC).
This would be the first study:
- targeting glucose metabolism,
- testing the effectiveness of acetazolamide in oncology,
- testing the synergy radiotherapy / targeting glycolytic metabolism,
- trying to manipulate the anti-tumor immune system indirectly, by decreasing extracellular acidosis.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Phase I study with a prospective, multicenter, non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized Small cell lung cancer or in combinaison with radioimmunotherapy in patients with extensive Small cell lung cancer
| Arm | Type | Receives |
|---|---|---|
| Localized SCLC | Experimental | Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapynon randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer |
| Extensive SCLC | Other | Drug: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLCnon randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with radioimmunotherapy in patients with extensive small cell lung cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age > or = 18 years,
- Performance Status 0 to 2,
- Patient with an histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer,
- Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group) or Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group) Note: The decision of the Multidisciplinary Consultation Team must be notified in the patient's medical file,
- Evaluation lesion according to the criteria RECIST 1.1 and / or according to the criteria PERCIST 1.0,
Key exclusion criteria (10 listed)
- Patient with metastatic disease,
- History of thoracic irradiation or near / in the thoracic irradiation field,
- Patient who refuses to participate in the study or unable to agree,
- Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure:
- Contraindication to acetazolamide: hypersensitivity to acetazolamide, severe hepatic, renal or adrenal insufficiency, sulfonamide intolerance, history of renal colic, allergy to wheat other than celiac disease,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| acetazolamide in combination with platinum and etoposide-based radiochemotherapyRadiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase). | Drug | Localized SCLC |
| acetazolamide in combination with radioimmunotherapy in patients with extensive SCLCacetazolamide in combination with radioimmunotherapy in patients with extensive SCLC | Drug | Extensive SCLC |
Primary outcome
To identify the Tolerated Maximum Dose (DMT) and Recommended Dose (DR) of acetazolamide in combination with radiotherapy combined with platinum and etoposide chemotherapy (localized SCLC) or with radioimmunotherapy (extensive SCLC)
Time frame: 8 months
The frequency of limiting dose toxicities determined by the number of Adverse Events as Assessed by CTCAE v4.03 : * during the 6 weeks of treatment with acetazolamide / chemoradiation based on platinum and etoposide and in the first 6 months of follow-up after the last administration of the treatment * during the 10 days of treatment with acetazolamide / radioimmunotherapy and in the first 6 months after the last administration of the treatment with radioimmunotherapy, for the "extensive SCLC" subgroup
9 secondary outcomes
To determine the overall tolerance of the association acetazolamide and radiochemotherapy (localized SCLC) or of the association acetazolamide and radioimmunotherapy (extensive)SCLC)
Time frame: 27 months
To evaluate the effectiveness of the treatment
Time frame: 24 months
To evaluate the effectiveness of the treatment
Time frame: 24 months
To identify predictive factors for response to acetazolamide
Time frame: 3 months
To identify predictive factors for response to acetazolamide
Time frame: 30 months
To evaluate progression-free survival at 24 months
Time frame: 24 months
To evaluate overall survival at 24 months
Time frame: 24 months
To determine the compliance of acetazolamide
Time frame: 27 months
To evaluate the quality of life
Time frame: 27 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vanessa VIDAL study director
Centre Antoine Lacassagne
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing acetazolamide in combination with platinum and etoposide-based radiochemotherapy and acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC in people with Small Cell Lung Cancer, run by Centre Antoine Lacassagne at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France, Monaco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jérôme DOYEN, PH (+33492031270, jerome.doyen@nice.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To identify the Tolerated Maximum Dose (DMT) and Recommended Dose (DR) of acetazolamide in combination with radiotherapy combined with platinum and etoposide chemotherapy (localized SCLC) or with radioimmunotherapy (extensive SCLC) (time frame: 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.